TG Therapeutics, Inc. (TGTX)
- Sector
- Biotechnology
- Last price
- $62.76
- As of
Kresmion compiles this page from TGTX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
TG THERAPEUTICS, INC. (TGTX): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-09.
See the full TGTX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TGTX on one page. Preview it with sample data, then open it live with a free account.
Preview the TGTX dossierActive events for TGTX
- mediumEarnings below estimates
Q3-2026: Missed consensus by 6.4%, EPS $0.35 vs $0.3741 estimate
- high13F: funds added
10 tracked funds increased TGTX this 2026Q2, institutional consensus
- high13F: funds added
3 tracked funds increased TGTX this 2026Q2, institutional consensus
- high13F: large reduction
Point72 Asset Management, L.P. cut 97% of TGTX (2026Q2)
- high13F: large reduction
Point72 Asset Management, L.P. cut 59% of TGTX (2026Q2)
FREE, NO ACCOUNT
Every event on TGTX, as it fires
You are seeing 5 of 22 events recorded on TGTX since 2026-05-31.
The five above landed across 3 days. The other 17 were recorded on 3 other days. 14 of the 22 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
TGTX positions held by the managers we follow (2026Q3)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 88322Q108 · 2026Q3 | $25M | 0.03% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TGTX
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on TGTX
TGTX against its peers
TGTX's operating margin of 20.0% ranks in the 83rd percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-09-30.
| Metric | TGTX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 616M USD | 152M USD | 68 | 16 |
| Gross margin | 83.7% | 84.8% | 50 | 6 |
| Operating margin | 20.0% | -129.0% | 83 | 14 |
| Net margin | 72.6% | -132.1% | 97 | 14 |
| Return on equity | 69.0% | -25.4% | 93 | 20 |
| P / E | 22.7x | n/a | n/a | 4 |
| 1 year | 106.9% | 41.7% | 79 | 20 |
Peers (23): SMMT, SYRE, PCVX, NUVL.D, MDGL, CRNX.D, KRYS, APGE.D, PRAX, KYMR, HALO, PTGX, BMRN, CYTK, RYTM, ALKS, ABVX, CAI, ORKA, KOD, CGON, ARWR, IBRX. Left out: SBMFF (no annual filing), BCHMY (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-09-30. Every figure is one full fiscal year read from one annual filing (TGTX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in TGTX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on TGTX in the last 180 days.
Upstream: SEC EDGAR filings for TGTX
Kresmion, "TG THERAPEUTICS, INC. (TGTX) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/TGTX. Upstream data: SEC EDGAR filings for TGTX.
Link to this data (HTML):
<a href="https://kresmion.com/research/TGTX">TG THERAPEUTICS, INC. (TGTX) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow TGTX on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to TGTX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.